2022
DOI: 10.3390/jdb10030031
|View full text |Cite
|
Sign up to set email alerts
|

The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review

Abstract: Protein kinase CK2 (CK2) is a ubiquitous holoenzyme involved in a wide array of developmental processes. The involvement of CK2 in events such as neurogenesis, cardiogenesis, skeletogenesis, and spermatogenesis is essential for the viability of almost all organisms, and its role has been conserved throughout evolution. Further into adulthood, CK2 continues to function as a key regulator of pathways affecting crucial processes such as osteogenesis, adipogenesis, chondrogenesis, neuron differentiation, and the i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 213 publications
0
9
0
Order By: Relevance
“…Protein kinase 2 (CK2) phosphorylates over 200 proteins, impacting such pathways as Wnt, Smad-dependent signaling, Akt/PI3K, MAPK, and NF-κB, as well as the DDR proteins XRCC4, XRCC1, DNA PK, and APE1 ( 113 ). CK2 phosphorylation of NPM1 at S125 is important for the nucleolar organization ( 114 ).…”
Section: Cancer Npm1 and Targetingmentioning
confidence: 99%
“…Protein kinase 2 (CK2) phosphorylates over 200 proteins, impacting such pathways as Wnt, Smad-dependent signaling, Akt/PI3K, MAPK, and NF-κB, as well as the DDR proteins XRCC4, XRCC1, DNA PK, and APE1 ( 113 ). CK2 phosphorylation of NPM1 at S125 is important for the nucleolar organization ( 114 ).…”
Section: Cancer Npm1 and Targetingmentioning
confidence: 99%
“…For example, one such promising drug is CX-4945 which not only inhibits DYRK1A but also targets casein kinase II and CLK. This drug is a potent inhibitor of DYRK1A in vitro , as well as in Drosophila and mouse models of DYRK1A overexpression and is currently in clinical trials for treating cancer and COVID-19 ( Siddiqui-Jain et al, 2012 ; Kim et al, 2016 ; Halloran et al, 2022 ; Grygier et al, 2023 ). In addition, a kinome-wide polypharmacological profile study of the four Food and Drug Administration (FDA)-approved inhibitors of poly (ADP-ribose) polymerase (PARP) revealed an unexpected submicromolar activity of niraparib against DYRK1A and DYRK1B ( Antolin et al, 2020 ; Sandhu et al, 2022 ).…”
Section: Dyrk1a In Human Disease and Therapeutic Developmentmentioning
confidence: 99%
“…The OPL2-mTb-YFP samples showed enrichment of the polarity protein SOK3 and its effector ANGUSTIFOLIA (AN) [37], DLC1, a poorly characterized microtubule-associated protein abundant in all plants (Cao et al, 2017) and multiple regulatory (CKB) and catalytic (CKA) subunits of protein kinase CKII [21]. CKII is ubiquitous and multifunctional, participating in several eukaryotic developmental pathways [38,39]. The CKII target recognition motif is known and is present in OPL2 [17,40].…”
Section: Proximity Labeling Of Polar Domains In Stomatal Lineage Cell...mentioning
confidence: 99%